SLN

$12.36-$0.10 (-0.80%)live

Compare

Change$-10.64

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held · Bookmarked

0 · 0

portfolios · users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$774.4M

62M shares

52-week range

$4.19 – $17.58

61% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

ADRC

P/S (TTM)

317

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$438143	-94.4%	$-0.49	$-0.69–$-0.17	—	3
2027	$1M	+186.9%	$-0.58	$-1.12–$-0.17	—	3
2028	$697651	-44.5%	$-0.66	$-1.30–$-0.05	—	1
2029	$850000	+21.8%	$-0.62	$-1.22–$-0.05	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-10	$-0.13	$-0.26	-104.4%
2026-05-07	$-0.33	$-0.32	+3.0%
2026-03-05	$-0.32	$-0.25	+21.9%
2025-11-06	$-0.40	$-0.45	-12.5%
2025-08-07	$-0.27	$-0.54	-100.0%
2025-05-08	$-0.18	$-0.60	-233.3%
2025-02-27	$-0.45	$0.27	+160.0%
2024-11-14	$-0.42

DCF fair valuemodel estimate

Intrinsic value

$1.84

Price

$12.36

Implied downside

-85%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
SLNSilence Therapeutics plc	$12.33	-1.04%	$582M	—
ACIUAC Immune S.A.	$2.71	+0.93%	$275M	—
ALDXAldeyra The	$1.38	+0.73%	$83M	—
AMRNAmarin Corporation plc	$13.95	+0.11%	$288M	—
ANROAlto Neuroscience, Inc.	$30.97	+2.40%

Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

www.silence-therapeutics.com

Employees: 88
IPO / List date: Sep 8, 2020
HQ: LONDON

Held by traders on TradeandTell

No one on the platform currently holds SLN.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2024-06-30	39,100	$742.9K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded SLN yet.

$SLN chatter on StockTwits

Elessar66@Elessar666d
$SLN big candle up pre-market to 14+.. did i miss anything again?
View on StockTwits ↗
Elessar66@Elessar666d
$SLN why is stuck since read out ffs
View on StockTwits ↗
pir@SannieVerraderlijk6d
$SLN Added some here, will double if it falls to 11-12, Lp(a) asset was already shelved, it's not where the value is
View on StockTwits ↗
full name@nnnuuuBullishSep 9
$SLN sold out and took profits to $NKTR. think this still does well but out with 100% so not disappointed, think this still has legs but think the fallout from NVS isn't over.
View on StockTwits ↗
Elessar66@Elessar66Sep 6
$SLN big jump back up AH..
View on StockTwits ↗
laaarsas@laaarsasSep 5
$SLN FUCK I have to admit I should have sold at around 16 after data. The market gives you what it gives you. SP should have been 25 but market gave ~15. Then you have to accept it. Waiting for Lp(a) wa sly way of saying I did not accept what the market gave me. At least half should have been taken off the table. Was not super read up on the trial but from quick research it was apparent it was far from certain to hit. This was a failure of acceptance from my side. After ph3 divesiran the SP will likely be substantially higher than now. But that is a few years down the line.
View on StockTwits ↗
Elessar66@Elessar66Sep 4
$SLN wtf just happened AH?
View on StockTwits ↗
StockConsultant.com@StockConsultantSep 2
$SLN Silence Therapeutics stock, nice breakout, from Stocks to Watch at https://www.stockconsultant.com/?SLN
View on StockTwits ↗
User 2449@stockwitsuser2449BearishSep 1
$SLN here is the data for you "gurus"
View on StockTwits ↗
User 2449@stockwitsuser2449BearishSep 1
$SLN while this is not traded on all brokers as stock the options are available...gained here before from a previous spike playing options on the expected downside. making similar case again. there is unusually high implied volatility on the downside puts, although kind of show i have seen here before. September OTM puts reaching ~790% IV, while October also shows extremely elevated downside IV. This doesn’t mean the market is predicting a specific price—it means downside protection is extremely expensive, suggesting traders are pricing significant tail risk into the September/October expirations. If selling of some of those shares from last months offer starts, the options structure suggests the potential for a sharp, nonlinear move lower rather than a normal gradual pullback. watch for 12.50 over the next 2 months and play caustiously glta
View on StockTwits ↗
R2@LIGatorBullishSep 1
$GLSI $SLN I have owned both for years. Both are among my top holdings. I don’t think that SLN would catch GLSI in share price, but we are almost there. GLSI is overdue for a rally.
View on StockTwits ↗
Robert Schorr@BBRCAug 28
$NVS $IONS $NAMS $SLN Yes. The trial officially finished its core patient tracking phase in July 2026. Now they must execute a multi-month cleaning phase before unblinding the data. Phase 3 Horizon topline results are expected to hit the tape in late 2026 or early 2027.
View on StockTwits ↗
Elessar66@Elessar66Aug 28
$SLN Ph3 study start in 1H27. Mgmt will share detailed Ph2 data at on December 12–15, 2026. they intend to advance divesiran as quickly as possible and will share details on the Ph3 trial design post alignment with the FDA, but has already decided to advance the convenient dose
View on StockTwits ↗
Mason@masonatAug 28
$NVS $IONS $NAMS $SLN HORIZON finally finished. Results should be soon.
View on StockTwits ↗
JeremyDanie@JeremyDanieAug 28
$SLN Anyone see a catalyst for these shares before year-end?
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.